Index RUT
P/E -
EPS (ttm) -1.80
Insider Own 39.18%
Shs Outstand 110.16M
Perf Week 4.35%
Market Cap 143.33M
Forward P/E -
EPS next Y -0.10
Insider Trans -0.24%
Shs Float 72.65M
Perf Month 36.67%
Income -203.84M
PEG -
EPS next Q -0.33
Inst Own 60.07%
Short Float 10.51%
Perf Quarter -3.23%
Sales 2.26M
P/S 63.42
EPS this Y 61.33%
Inst Trans 1.52%
Short Ratio 12.15
Perf Half Y -61.17%
Book/sh 1.18
P/B 1.02
EPS next Y 86.43%
ROA -82.73%
Short Interest 7.64M
Perf Year -31.43%
Cash/sh 1.24
P/C 0.97
EPS next 5Y -
ROE -96.56%
52W Range 0.81 - 5.20
Perf YTD -69.54%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -144.93%
52W High -76.90%
Beta 0.63
Dividend TTM -
Quick Ratio 4.57
Sales past 5Y 0.00%
Gross Margin 5.04%
52W Low 47.86%
ATR (14) 0.11
Dividend Ex-Date -
Current Ratio 4.71
EPS Y/Y TTM -12.04%
Oper. Margin -9326.33%
RSI (14) 60.11
Volatility 7.60% 12.51%
Employees 94
Debt/Eq 0.00
Sales Y/Y TTM -
Profit Margin -9003.40%
Recom 1.50
Target Price 8.65
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q 13.75%
Payout -
Rel Volume 1.98
Prev Close 1.22
Sales Surprise -54.72%
EPS Surprise -7.15%
Sales Q/Q -
Earnings Aug 14 BMO
Avg Volume 628.20K
Price 1.20
SMA20 20.84%
SMA50 11.46%
SMA200 -52.31%
Trades
Volume 1,244,499
Change -1.64%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-05-24 Upgrade
Guggenheim
Neutral → Buy
$9
Mar-26-24 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$4 → $10
Dec-19-23 Upgrade
Morgan Stanley
Underweight → Equal-Weight
$1 → $4
May-01-23 Initiated
H.C. Wainwright
Buy
$5
Sep-12-24 07:01AM
Sep-05-24 07:01AM
Sep-04-24 07:01AM
Sep-03-24 07:01AM
Aug-27-24 07:01AM
02:43AM
Loading…
Aug-15-24 02:43AM
(Thomson Reuters StreetEvents) +6.12%
Aug-14-24 09:10AM
08:01AM
Aug-12-24 04:01PM
(GlobeNewswire) -6.31%
+9.84%
Jul-01-24 07:01AM
Jun-14-24 07:01AM
Jun-03-24 04:01PM
May-31-24 07:05AM
07:00AM
May-29-24 07:00AM
07:00AM
Loading…
May-22-24 07:00AM
May-13-24 04:01PM
10:44AM
May-10-24 03:25PM
May-09-24 10:56PM
04:01PM
May-07-24 07:30AM
May-02-24 05:13PM
Apr-30-24 07:30AM
Apr-15-24 07:30AM
Apr-12-24 07:30AM
Apr-04-24 04:01PM
(GlobeNewswire) -8.91%
-7.82%
Mar-28-24 01:53PM
07:00AM
Mar-22-24 03:28PM
03:04PM
Loading…
03:04PM
Feb-05-24 04:02PM
Jan-29-24 12:35PM
Jan-12-24 12:00PM
Jan-03-24 07:00AM
Dec-23-23 05:29AM
Dec-19-23 11:52AM
Dec-18-23 07:00AM
Nov-13-23 10:21AM
Nov-10-23 08:35AM
(Thomson Reuters StreetEvents)
Nov-09-23 04:01PM
Nov-02-23 04:01PM
Oct-31-23 04:01PM
Sep-11-23 07:00AM
Sep-06-23 08:17PM
07:00AM
Sep-05-23 07:00AM
Aug-29-23 01:13PM
Aug-15-23 05:45AM
Aug-11-23 06:43AM
(Thomson Reuters StreetEvents)
Aug-10-23 04:01PM
Aug-03-23 04:01PM
Jul-27-23 04:01PM
Jul-17-23 02:15PM
07:00AM
Jun-26-23 07:00AM
Jun-22-23 01:07PM
07:00AM
Jun-01-23 07:00AM
May-23-23 06:25AM
(Simply Wall St.) +19.72%
May-11-23 04:01PM
May-04-23 04:01PM
Apr-25-23 04:01PM
07:00AM
Apr-14-23 09:35AM
Apr-12-23 07:00AM
Mar-30-23 04:01PM
Mar-28-23 04:58AM
Mar-24-23 06:41AM
(Thomson Reuters StreetEvents) -8.39%
Mar-23-23 04:01PM
Mar-22-23 04:30PM
Mar-16-23 07:00AM
Mar-06-23 07:00AM
Feb-28-23 07:00AM
Feb-03-23 07:30AM
Jan-27-23 05:59PM
Jan-02-23 12:00PM
Dec-19-22 07:00AM
Dec-13-22 02:37PM
Dec-06-22 04:01PM
(GlobeNewswire) -8.45%
+5.90%
Nov-22-22 09:20PM
(American City Business Journals)
Nov-17-22 01:58PM
07:00AM
Nov-10-22 04:01PM
Nov-09-22 07:00AM
Nov-02-22 07:00AM
Oct-24-22 04:01PM
Oct-17-22 02:37PM
(American City Business Journals)
Oct-13-22 04:26PM
(The Wall Street Journal) +5.44%
-6.02%
04:01PM
Oct-12-22 04:01PM
Oct-03-22 08:05AM
Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
MCGUIRE TERRANCE Director May 29 '24 Sale 1.66 112,381 186,575 4,688,079 May 31 05:09 PM Adimab, LLC 10% Owner Jan 19 '24 Sale 3.95 5,000,000 19,750,000 21,687,906 Jan 22 04:18 PM
Index RUT
P/E -
EPS (ttm) -1.81
Insider Own 21.73%
Shs Outstand 84.88M
Perf Week -4.64%
Market Cap 559.59M
Forward P/E -
EPS next Y -1.39
Insider Trans -0.79%
Shs Float 76.18M
Perf Month 8.70%
Income -160.66M
PEG -
EPS next Q -0.53
Inst Own 73.32%
Short Float 4.55%
Perf Quarter 25.82%
Sales 55.27M
P/S 10.12
EPS this Y -22.79%
Inst Trans 0.69%
Short Ratio 6.02
Perf Half Y -7.70%
Book/sh 1.55
P/B 3.72
EPS next Y 27.59%
ROA -25.11%
Short Interest 3.47M
Perf Year -5.27%
Cash/sh 5.17
P/C 1.11
EPS next 5Y -10.70%
ROE -92.64%
52W Range 3.66 - 8.90
Perf YTD -27.94%
Dividend Est. -
P/FCF -
EPS past 5Y -15.76%
ROI -90.22%
52W High -35.39%
Beta 0.68
Dividend TTM -
Quick Ratio 3.52
Sales past 5Y 158.96%
Gross Margin 83.56%
52W Low 57.10%
ATR (14) 0.37
Dividend Ex-Date -
Current Ratio 3.52
EPS Y/Y TTM -4.52%
Oper. Margin -338.94%
RSI (14) 54.94
Volatility 7.62% 6.46%
Employees 244
Debt/Eq 0.24
Sales Y/Y TTM -45.84%
Profit Margin -290.66%
Recom 1.82
Target Price 13.75
Option/Short Yes / Yes
LT Debt/Eq 0.18
EPS Q/Q -2539.63%
Payout -
Rel Volume 2.72
Prev Close 6.14
Sales Surprise 5.02%
EPS Surprise 20.16%
Sales Q/Q -73.17%
Earnings Aug 07 AMC
Avg Volume 576.13K
Price 5.75
SMA20 7.45%
SMA50 4.34%
SMA200 -1.51%
Trades
Volume 1,565,737
Change -6.35%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-14-23 Upgrade
Stifel
Hold → Buy
$8 → $15
Dec-12-23 Initiated
Deutsche Bank
Buy
$12
Sep-25-23 Initiated
Goldman
Sell
$4
Sep-22-23 Initiated
Cantor Fitzgerald
Overweight
$13
Jan-06-23 Downgrade
BofA Securities
Buy → Neutral
$24 → $12
Sep-09-22 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$27 → $13
Jul-07-22 Initiated
Mizuho
Buy
$15
Apr-13-22 Initiated
Goldman
Sell
$9
Mar-08-22 Downgrade
Stifel
Buy → Hold
$32 → $18
Sep-27-21 Initiated
William Blair
Outperform
Jan-15-21 Resumed
BofA Securities
Buy
$35
Jun-24-20 Initiated
H.C. Wainwright
Buy
$41
Apr-28-20 Initiated
Goldman
Buy
$32
Mar-06-20 Initiated
Citigroup
Buy
$40
Feb-27-20 Initiated
Barclays
Overweight
$36
Feb-19-20 Initiated
Stifel
Buy
$44
Nov-21-19 Initiated
BTIG Research
Buy
$28
Mar-04-19 Initiated
SVB Leerink
Outperform
Mar-04-19 Initiated
Morgan Stanley
Overweight
$27
Mar-04-19 Initiated
BofA/Merrill
Buy
$26
Show Previous Ratings
Sep-19-24 08:00AM
Aug-29-24 07:00AM
Aug-23-24 07:19PM
Aug-07-24 06:15PM
05:11PM
(Associated Press Finance)
04:05PM
Loading…
04:05PM
Jul-31-24 04:05PM
Jul-28-24 08:05AM
Jul-23-24 07:00AM
Jun-29-24 08:43PM
06:30PM
Jun-20-24 07:00AM
Jun-10-24 07:00AM
Jun-03-24 07:00AM
May-09-24 07:00AM
11:55PM
Loading…
May-08-24 11:55PM
06:25PM
05:19PM
(Associated Press Finance)
04:05PM
Apr-25-24 10:02AM
Feb-28-24 02:02PM
(Thomson Reuters StreetEvents)
10:13AM
07:00AM
Feb-27-24 04:46PM
04:23PM
(Associated Press Finance)
04:05PM
Feb-20-24 04:05PM
10:00AM
Feb-08-24 07:00AM
06:48AM
07:00AM
Loading…
Feb-07-24 07:00AM
Jan-25-24 12:00PM
Jan-23-24 07:32AM
Jan-19-24 09:20AM
Jan-17-24 08:54AM
Jan-16-24 04:01PM
Jan-08-24 01:25PM
(Investor's Business Daily) +7.34%
Dec-05-23 09:55AM
Nov-28-23 07:00AM
Nov-14-23 09:35AM
Nov-08-23 07:00AM
Nov-07-23 06:02PM
(Associated Press Finance) +5.12%
05:11PM
04:05PM
Oct-27-23 07:00AM
Sep-14-23 01:12AM
Sep-08-23 12:10PM
Sep-07-23 07:00AM
Aug-31-23 07:00AM
Aug-10-23 09:55AM
Aug-03-23 05:45PM
04:43PM
(Associated Press Finance)
04:05PM
Jul-27-23 08:30AM
Jul-13-23 01:29PM
Jun-06-23 07:00AM
Jun-01-23 07:29AM
May-09-23 09:55AM
May-05-23 06:31AM
(Simply Wall St.) +10.27%
May-04-23 07:35PM
06:27PM
04:05PM
May-02-23 07:00AM
May-01-23 10:01AM
Apr-27-23 10:03AM
Apr-13-23 12:59PM
08:30AM
Mar-01-23 04:05PM
Feb-28-23 04:05PM
Feb-20-23 10:00AM
Feb-17-23 06:01AM
Feb-16-23 10:01AM
Dec-21-22 05:01AM
Dec-08-22 04:30PM
Nov-29-22 11:05AM
Nov-10-22 05:13AM
(Simply Wall St.) +19.62%
Nov-08-22 07:45PM
04:05PM
Nov-07-22 07:00AM
Nov-04-22 11:05AM
Nov-03-22 04:30PM
Oct-13-22 08:00AM
Oct-06-22 04:30PM
Sep-12-22 07:00AM
Sep-07-22 07:00AM
Aug-09-22 09:55AM
Aug-06-22 08:33AM
Aug-04-22 07:15PM
04:05PM
Jul-08-22 10:54AM
Jul-07-22 05:59PM
(American City Business Journals)
Jun-08-22 07:00AM
May-28-22 08:20AM
May-27-22 04:30PM
May-05-22 06:25PM
04:05PM
May-04-22 07:00AM
May-02-22 07:47AM
Apr-27-22 03:03PM
Mar-29-22 04:05PM
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GRASSO MARC Chief Financial Officer Sep 03 '24 Sale 4.88 7,297 35,620 130,740 Sep 04 04:44 PM Rosenthal Arnon Chief Executive Officer Sep 03 '24 Sale 4.88 26,499 129,387 1,948,746 Sep 04 04:15 PM Kenkare-Mitra Sara President and Head of R&D Sep 03 '24 Sale 4.88 13,926 67,981 291,715 Sep 04 04:15 PM Romano Gary Chief Medical Officer Sep 03 '24 Sale 4.88 8,478 41,385 179,795 Sep 04 04:15 PM Arnon Rosenthal Officer Sep 03 '24 Proposed Sale 5.28 24,359 128,616 Aug 30 05:18 PM Sara Kenkare-Mitra Officer Sep 03 '24 Proposed Sale 5.28 12,796 67,563 Aug 30 05:18 PM Marc Grasso Officer Sep 03 '24 Proposed Sale 5.28 6,703 35,392 Aug 30 05:18 PM Gary Romano Officer Sep 03 '24 Proposed Sale 5.28 7,788 41,121 Aug 30 05:18 PM SCHELLER RICHARD H Director Aug 22 '24 Sale 5.16 44,250 228,388 35,000 Aug 23 04:05 PM SCHELLER RICHARD H Director Aug 22 '24 Proposed Sale 4.75 44,250 210,188 Aug 22 05:31 PM Hammond Paula Director Aug 12 '24 Sale 5.06 10,500 53,179 60,209 Aug 13 07:55 PM Yaffe Kristine Director Aug 12 '24 Sale 5.06 5,000 25,309 67,709 Aug 13 07:55 PM PAULA HAMMOND Director Aug 12 '24 Proposed Sale 5.06 10,500 53,179 Aug 12 04:34 PM Romano Gary Chief Medical Officer Jun 03 '24 Sale 4.80 8,040 38,582 188,273 Jun 04 06:05 PM Kenkare-Mitra Sara President and Head of R&D Jun 03 '24 Sale 4.80 13,206 63,373 305,641 Jun 04 06:05 PM Rosenthal Arnon Chief Executive Officer Jun 03 '24 Sale 4.80 25,135 120,618 1,975,245 Jun 04 06:05 PM GRASSO MARC Chief Financial Officer Jun 03 '24 Sale 4.80 6,920 33,208 138,037 Jun 04 06:05 PM GRASSO MARC Chief Financial Officer Mar 04 '24 Sale 6.92 5,716 39,562 144,957 Mar 05 06:00 PM Rosenthal Arnon Chief Executive Officer Mar 04 '24 Sale 6.92 18,837 130,386 2,000,380 Mar 05 06:00 PM Romano Gary Chief Medical Officer Mar 04 '24 Sale 6.92 6,001 41,554 196,313 Mar 05 06:00 PM Kenkare-Mitra Sara President and Head of R&D Mar 04 '24 Sale 6.92 10,169 70,387 318,847 Mar 05 06:00 PM GRASSO MARC Chief Financial Officer Dec 04 '23 Sale 5.56 4,574 25,431 150,673 Dec 06 06:30 PM Romano Gary Chief Medical Officer Dec 04 '23 Sale 5.56 5,035 27,995 202,314 Dec 06 06:30 PM Rosenthal Arnon Chief Executive Officer Dec 04 '23 Sale 5.56 23,831 132,500 2,019,217 Dec 06 06:30 PM Kenkare-Mitra Sara President and Head of R&D Dec 04 '23 Sale 5.56 12,519 69,606 329,016 Dec 06 06:30 PM
Index -
P/E -
EPS (ttm) -5.19
Insider Own 23.24%
Shs Outstand 2.47M
Perf Week 1.03%
Market Cap 7.94M
Forward P/E -
EPS next Y -
Insider Trans 0.00%
Shs Float 2.08M
Perf Month 5.40%
Income -12.74M
PEG -
EPS next Q -
Inst Own 38.74%
Short Float 0.63%
Perf Quarter 32.58%
Sales 0.00M
P/S -
EPS this Y -
Inst Trans 20.41%
Short Ratio 2.03
Perf Half Y 4.64%
Book/sh 3.49
P/B 0.84
EPS next Y -
ROA -103.82%
Short Interest 0.01M
Perf Year -19.50%
Cash/sh 1.69
P/C 1.73
EPS next 5Y -
ROE -150.23%
52W Range 1.75 - 5.25
Perf YTD -12.54%
Dividend Est. -
P/FCF -
EPS past 5Y 36.06%
ROI -145.10%
52W High -44.19%
Beta 1.91
Dividend TTM -
Quick Ratio 3.68
Sales past 5Y -33.97%
Gross Margin -
52W Low 67.42%
ATR (14) 0.27
Dividend Ex-Date -
Current Ratio 3.68
EPS Y/Y TTM 60.58%
Oper. Margin 0.00%
RSI (14) 49.93
Volatility 4.69% 7.67%
Employees 1
Debt/Eq 0.00
Sales Y/Y TTM -100.00%
Profit Margin -
Recom 1.00
Target Price 80.00
Option/Short No / Yes
LT Debt/Eq 0.00
EPS Q/Q 71.25%
Payout -
Rel Volume 0.53
Prev Close 2.83
Sales Surprise -13.92%
EPS Surprise -3.33%
Sales Q/Q -
Earnings -
Avg Volume 6.45K
Price 2.93
SMA20 0.79%
SMA50 -3.54%
SMA200 -1.36%
Trades
Volume 3,409
Change 3.53%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-20-21 Initiated
Truist
Buy
$14
Sep-24-21 Initiated
Cantor Fitzgerald
Overweight
$7
Jun-03-19 Initiated
Credit Suisse
Neutral
Aug-07-24 07:00AM
Jun-21-24 07:52AM
May-08-24 08:52AM
Apr-05-24 06:53AM
Mar-24-24 03:54PM
08:00AM
Loading…
Dec-04-23 08:00AM
Nov-30-23 06:16PM
(GlobeNewswire) +7.39%
+14.06%
Aug-02-23 08:39PM
(American City Business Journals)
Jul-31-23 07:00AM
Jun-01-23 04:00PM
May-15-23 01:00PM
May-12-23 02:59PM
May-11-23 06:00PM
06:00PM
Apr-03-23 07:30AM
07:00AM
Loading…
Mar-27-23 07:00AM
Mar-22-23 04:40PM
Nov-22-22 07:00AM
Nov-09-22 06:34AM
Oct-07-22 02:31PM
(American City Business Journals) -9.66%
Oct-06-22 12:46PM
08:00AM
Aug-09-22 05:35PM
04:00PM
Aug-08-22 09:22AM
(Simply Wall St.) +27.76%
Jul-28-22 07:00AM
Jul-26-22 07:00AM
Jun-28-22 09:00AM
Jun-22-22 08:30AM
Jun-17-22 11:20AM
08:00AM
Loading…
08:00AM
Jun-10-22 07:00AM
Jun-06-22 07:00AM
May-11-22 09:30AM
May-04-22 04:01PM
(GlobeNewswire) +8.62%
-5.39%
Feb-27-22 06:39AM
Feb-24-22 04:01PM
Feb-23-22 08:00AM
Feb-01-22 05:30AM
Jan-26-22 08:00AM
Dec-15-21 10:00AM
Nov-25-21 04:47AM
Nov-11-21 05:32PM
Nov-09-21 04:01PM
Nov-08-21 12:00PM
(American City Business Journals)
Oct-20-21 04:24PM
(Benzinga) +10.90%
-5.42%
Oct-11-21 03:34AM
Oct-10-21 09:37AM
Sep-22-21 08:00AM
Sep-08-21 08:00AM
Aug-26-21 07:19AM
Aug-23-21 05:00PM
Jul-29-21 05:00PM
Jul-22-21 04:30PM
Jul-12-21 02:24AM
Jul-09-21 06:14AM
Jul-08-21 07:22PM
04:30PM
Jun-04-21 10:27AM
08:00AM
08:00AM
May-27-21 04:30PM
May-25-21 07:00AM
May-09-21 03:36AM
Apr-27-21 09:00AM
Apr-26-21 07:00AM
Apr-21-21 07:30AM
Apr-20-21 07:00AM
Mar-24-21 04:05PM
(PR Newswire) -6.80%
+5.78%
Mar-22-21 02:23AM
Mar-19-21 07:46AM
Mar-18-21 05:00PM
Feb-25-21 07:00AM
Jan-25-21 07:00AM
Jan-21-21 12:52AM
Jan-04-21 07:00AM
Dec-21-20 07:30AM
Dec-02-20 11:27PM
Nov-15-20 07:55AM
Nov-05-20 07:00AM
Oct-14-20 01:09PM
10:07AM
07:00AM
07:00AM
Oct-04-20 09:52AM
Sep-04-20 07:00AM
Aug-25-20 07:00AM
Aug-20-20 11:01AM
Aug-03-20 09:25AM
Jul-30-20 09:00AM
Jul-17-20 07:00AM
Jul-06-20 03:17PM
Jul-05-20 02:45PM
Jun-18-20 04:01PM
May-22-20 07:52AM
Apr-10-20 07:00AM
Mar-23-20 06:50AM
(Simply Wall St.) +18.94%
Jan-13-20 07:00AM
Jan-12-20 05:05PM
Dec-24-19 08:17AM
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite